Literature DB >> 26623024

Topiramate effects lipolysis in 3T3-L1 adipocytes.

Gabriela Poltronieri Campagnaro Martins1, Camila Oliveira Souza2, Scherolin Marques1, Thais Fernandes Luciano1, Bruno Luiz DA Silva Pieri1, José César Rosa2, Adelino Sanchez Ramos DA Silva3, José Rodrigo Pauli4, Dennys Esper Cintra4, Eduardo Rochete Ropelle4, Bruno Rodrigues5, Fabio Santos DE Lira6, Claudio Teodoro DE Souza1.   

Abstract

Studies have shown that topiramate (TPM)-induced weight loss can be dependent on the central nervous system (CNS). However, the direct action of TPM on adipose tissue has not been tested previously. Thus, the present study aimed to examine whether TPM modulates lipolysis in 3T3-L1. The 3T3-L1 cells were incubated in 50 µM TPM for 30 min. The β-adrenergic stimulator, isoproterenol, was used as a positive control. The release of lactate dehydrogenase, non-esterified fatty acid, glycerol and incorporation of 14C-palmitate to lipid were analyzed. The phosphorylation of protein kinase A (PKA), hormone-sensitive lipase (HSL), adipocyte triglyceride lipase (ATGL) and perilipin A, as well as the protein levels of comparative genetic identification 58 (CGI-58) were assessed. The levels of glycerol and non-esterified fatty acid increased markedly when the cells were treated with TPM. The TPM effects were similar to the isoproterenol positive control. Additionally, TPM reduced lipogenesis. These results were observed without any change in cell viability. Finally, the phosphorylation of PKA, HSL, ATGL and perilipin A, as well as the protein levels of CGI-58 were increased compared to the control cells. These results were similar to those observed in the cells treated with isoproterenol. The present results show that TPM increased the phosphorylation of pivotal lipolytic enzymes, which induced lipolysis in 3T3-L1 adipocytes, suggesting that this drug may act directly in the adipose tissue independent from its effect on the CNS.

Entities:  

Keywords:  3T3-L1 adipocytes; lipolysis; obesity; topiramate; weight loss

Year:  2015        PMID: 26623024      PMCID: PMC4660592          DOI: 10.3892/br.2015.514

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  12 in total

1.  Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine.

Authors:  D M Abo-Elmatty; S A Zaitone
Journal:  Eur Rev Med Pharmacol Sci       Date:  2011-10       Impact factor: 3.507

2.  Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

Authors:  Kishore M Gadde; David B Allison; Donna H Ryan; Craig A Peterson; Barbara Troupin; Michael L Schwiers; Wesley W Day
Journal:  Lancet       Date:  2011-04-08       Impact factor: 79.321

3.  Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice.

Authors:  Andrea M Caricilli; Erica Penteado; Lélia L de Abreu; Paula G F Quaresma; Andressa C Santos; Dioze Guadagnini; Daniella Razolli; Francine C Mittestainer; Jose B Carvalheira; Licio A Velloso; Mario J A Saad; Patricia O Prada
Journal:  Endocrinology       Date:  2012-07-20       Impact factor: 4.736

4.  Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats.

Authors:  F Picard; Y Deshaies; J Lalonde; P Samson; D Richard
Journal:  Obes Res       Date:  2000-12

Review 5.  Topiramate-induced weight loss: a review.

Authors:  Alberto Verrotti; Alessandra Scaparrotta; Sergio Agostinelli; Sabrina Di Pillo; Francesco Chiarelli; Salvatore Grosso
Journal:  Epilepsy Res       Date:  2011-06-17       Impact factor: 3.045

6.  Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome.

Authors:  Achim Lass; Robert Zimmermann; Guenter Haemmerle; Monika Riederer; Gabriele Schoiswohl; Martina Schweiger; Petra Kienesberger; Juliane G Strauss; Gregor Gorkiewicz; Rudolf Zechner
Journal:  Cell Metab       Date:  2006-05       Impact factor: 27.287

Review 7.  Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis.

Authors:  Dawn L Brasaemle
Journal:  J Lipid Res       Date:  2007-09-18       Impact factor: 5.922

Review 8.  Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.

Authors:  Claudiu T Supuran; Anna Di Fiore; Giuseppina De Simone
Journal:  Expert Opin Emerg Drugs       Date:  2008-06       Impact factor: 4.191

9.  Predictors of weight loss in adults with topiramate-treated epilepsy.

Authors:  Elinor Ben-Menachem; Mette Axelsen; Else Hellebö Johanson; Anna Stagge; Ulf Smith
Journal:  Obes Res       Date:  2003-04

10.  Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation.

Authors:  Carole Sztalryd; Guoheng Xu; Heidi Dorward; John T Tansey; Juan A Contreras; Alan R Kimmel; Constantine Londos
Journal:  J Cell Biol       Date:  2003-06-16       Impact factor: 10.539

View more
  1 in total

1.  Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience.

Authors:  Flavio A Cadegiani; Gustavo C Diniz; Gabriella Alves
Journal:  BMC Obes       Date:  2017-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.